DDInter1232 DDInter1676
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mitomycin {u} (Compound) treats {v} (Disease) stomach cancer
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
Mitomycin {u} (Compound) upregulates {v} (Gene) STAP2
Mitomycin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mitomycin {u} (Compound) downregulates {v} (Gene) MRPL19
Mitomycin {u} (Compound) causes {v} (Side Effect) Acute respiratory distress syndrome
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclophosphamide
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Mitomycin (Compound) treats stomach cancer (Disease)
Mitomycin (Compound) binds ABCB1 (Gene)
Mitomycin (Compound) upregulates STAP2 (Gene)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mitomycin (Compound) downregulates MRPL19 (Gene)
Mitomycin (Compound) causes Acute respiratory distress syndrome (Side Effect)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine